Mixed Phenotype Acute Leukemia Clinical Trials in Memphis, Tennessee

4 studies are recruiting for mixed phenotype acute leukemia in Memphis, Tennessee right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

   This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide informat…

   Stage

   Phase 1

   Ages

   Up to 22

   Site

   Saint Jude Children's Research Hospital, Memphis, Tennessee

   Locations

   184 in total

   Run by

   PedAL BCU, LLC

   See if you can join NCT04726241 on ClinicalTrials.gov

2. Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

   This is a clinical trial testing whether the addition of one of two chemotherapy agents, dasatinib or venetoclax, can improve outcomes for children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma or mixed phenotype acute leukemia. Primary Objective * To evalua…

   Stage

   Phase 2

   Ages

   1 to 18

   Site

   St. Jude Children's Research Hospital, Memphis, Tennessee

   Locations

   4 in total

   Run by

   St. Jude Children's Research Hospital

   See if you can join NCT06390319 on ClinicalTrials.gov

3. Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

   The goal of this study is to provide sufficient therapy during the time a patients' B-cell Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy) risk category is being determined. The term "risk" refers to the chance of the ALL or LLy coming back after treatment. Primary Objectives * T…

   Stage

   Phase 4

   Ages

   1 to 18

   Site

   St. Jude Children's Research Hospital, Memphis, Tennessee

   Locations

   5 in total

   Run by

   St. Jude Children's Research Hospital

   See if you can join NCT06289673 on ClinicalTrials.gov

4. Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

   Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine the safety of this novel agent in pediatric patie…

   Stage

   Phase 1

   Ages

   1 to 21

   Site

   St. Jude Children's Research Hospital, Memphis, Tennessee

   Locations

   31 in total

   Run by

   Therapeutic Advances in Childhood Leukemia Consortium

   See if you can join NCT05476770 on ClinicalTrials.gov